COMPARISON OF POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT DARATUMUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND A PROTEASOME INHIBITORDARATUMUMAB/POMALIDOMIDE/DEXAMETHASONE VS POMALIDOMIDE/DEXAMETHASONE: